Equity Overview
Price & Market Data
Price: $8.40
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $672,275,712
Daily Volume: 0
Performance Metrics
1 Week: -3.23%
1 Month: -19.39%
3 Months: -25.93%
6 Months: -32.04%
1 Year: -22.22%
YTD: -32.91%
Company Details
Employees: 92
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.